4.7 Article

Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 1, Pages 183-189

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2014-206133

Keywords

-

Categories

Funding

  1. Swedish Foundation for Strategic Research
  2. The COMBINE public-private research programme
  3. Swedish Research Council
  4. ALF
  5. Strategic Research Programme for Epidemiology (SFO-Epi)
  6. EU-IMI BTCure
  7. Swedish Medical Research Council
  8. Swedish Research Council for Health, Working Life and Welfare

Ask authors/readers for more resources

Objectives Our objective was to estimate the risk of developing rheumatoid arthritis (RA) associated with a family history of non-RA arthritis-related diseases. This familial co-aggregation is of clinical interest since it is often encountered when assessing family history of RA specifically, but also informative on the genetic overlap between these diseases. Since anticitrullinated peptide antibodies/rheumatoid factor (RF)-positive and RF-negative RA have both specific and shared genetic factors, the familial co-aggregation was assessed separately for seropositive and seronegative disease. Methods Nested case-control study in prospectively recorded Swedish total population data. The Multi-Generation Register identified first-degree relatives. RA and arthritis-related diseases were ascertained through the nationwide patient register. RA serology was based on International Classification of Diseases tenth revision coded diagnoses, mainly reflecting RF. Familial risks were calculated using conditional logistic regression. Results were replicated using the Swedish rheumatology register. Results Familial co-aggregation was found between RA and every studied arthritis-related disease, but the magnitude varied widely, from juvenile idiopathic arthritis (JIA) (seropositive RA OR=3.98 (3.01 to 5.26); seronegative RA OR=5.70 (3.47 to 9.36)) to osteoarthritis (seropositive RA OR=1.03 (1.00 to 1.06); seronegative RA OR=1.05 (1.00 to 1.09)). The familial co-aggregation pattern of non-RA arthritis-related diseases was overall similar for seropositive and seronegative RA. Among those with family history of RA, relatives' other arthritis-related diseases conferred little or no additional risk. Conclusions Although family history of several arthritis-related diseases may be useful to predict RA (eg, lupus and JIA), others (eg, osteoarthritis and arthralgia) are less useful. Seropositive and seronegative RA had rather similar familial co-aggregation patterns with arthritis-related diseases, suggesting that the two RA subsets are similar in the genetic factors that overlap with these diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Smoking, use of smokeless tobacco, HLA genotypes and incidence of latent autoimmune diabetes in adults

Jessica Edstorp, Yuxia Wei, Emma Ahlqvist, Lars Alfredsson, Valdemar Grill, Leif Groop, Bahareh Rasouli, Elin P. Sorgjerd, Per M. Thorsby, Tiinamaija Tuomi, Bjorn O. Asvold, Sofia Carlsson

Summary: The study reveals that smoking and snus use are associated with a higher risk of LADA and type 2 diabetes, and smoking acts synergistically with HLA high-risk genotypes in the development of LADA.

DIABETOLOGIA (2023)

Article Rheumatology

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis

Viktor Molander, Hannah Bower, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling

Summary: Patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) have a higher incidence of venous thromboembolism (VTE) compared to those treated with other biological disease modifying antirheumatic drugs (bDMARDs), especially in terms of pulmonary embolism (PE).

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking

Bowen Tang, Qianwen Liu, Anna Ilar, Pernilla Wiebert, Sara Hagg, Leonid Padyukov, Lars Klareskog, Lars Alfredsson, Xia Jiang

Summary: This study examined the effects of occupational inhalable exposures on the development of rheumatoid arthritis (RA) and their interactions with smoking and RA-risk genes, specifically in relation to the presence of anticitrullinated protein antibodies (ACPA). The results showed that exposure to any occupational inhalable agents was associated with an increased risk for ACPA-positive RA. Furthermore, there was a significantly elevated risk for ACPA-positive RA among individuals who were exposed to occupational inhalable agents, smoked, and had a high genetic risk score (GRS). Significant interactions were found between occupational inhalable agents and smoking/genetic factors (high GRS or HLA-SE) in ACPA-positive RA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development

Bruno Raposo, Marcelo Afonso, Lena Israelsson, Heidi Waehaemaa, Ragnhild Stalesen, Fredrik Wermeling, Aase Haj Hensvold, Caroline Groenwall, Bence Rethi, Lars Klareskog, Vivianne Malmstrom

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Public, Environmental & Occupational Health

The Swedish medical birth register during five decades: documentation of the content and quality of the register

Sven Cnattingius, Karin Kallen, Anna Sandstrom, Henny Rydberg, Helena Mansson, Olof Stephansson, Thomas Frisell, Jonas F. Ludvigsson

Summary: The Swedish Medical Birth Register (MBR) provides high-quality pregnancy-related information on over 5 million births during five decades. It is an important resource for understanding the health of mothers and offspring in both the short and long term.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2023)

Article Clinical Neurology

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

Chiara Starvaggi Cucuzza, Elisa Longinetti, Nicolas Ruffin, Bjoern Evertsson, Ingrid Kockum, Maja Jagodic, Faiez Al Nimer, Thomas Frisell, Fredrik Piehl

Summary: This study aimed to determine the clinical and neuroradiologic disease activity, as well as B-cell repopulation dynamics, after implementing extended rituximab dosing in RRMS. The results showed that extended dosing intervals did not increase the risk of relapse in RRMS, and the dynamics of total B-cell and memory B-cell repopulation varied considerably.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Rheumatology

Temporal trends in adverse pregnancy outcomes in axial spondyloarthritis in Sweden: a cohort study

Matilda Morin, Thomas Frisell, Olof Stephansson, Karin Hellgren

Summary: This study aimed to assess the risks of adverse pregnancy outcomes in women with axial spondyloarthritis and investigate how the outcomes varied over time and with anti-rheumatic treatment. The results showed increased risks of preterm birth, pre-eclampsia, elective caesarean delivery, and serious infant infection in women with axial spondyloarthritis compared to the general population. However, there was a trend of improvement in pregnancy outcomes over time, coinciding with increased use of biological DMARDs.

LANCET RHEUMATOLOGY (2023)

Article Rheumatology

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Benedicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindstroem, Johan Askling

Summary: The objective of this study was to assess and compare the incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA). The study found that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling, ARTIS grp

Summary: This study assessed the cancer risks associated with Janus kinase inhibitors (JAKi) compared to biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. The results showed that, in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), the short-term risk of cancers other than non-melanoma skin cancer (NMSC) was not higher with JAKi compared to tumor necrosis factor inhibitors (TNFi), but there was evidence of an increased risk for NMSC.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Clinical Neurology

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study

Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M. Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, Neda Razaz

Summary: This study aimed to investigate the association between multiple sclerosis (MS) in mothers and the risks of adverse pregnancy and perinatal outcomes. A population-based retrospective cohort study in Sweden showed that mothers with MS had a higher risk of obstetric complications and their newborns had an increased risk of preterm birth and being small for gestational age compared to MS-free mothers. However, exposure to disease-modifying therapy (DMT) during pregnancy did not lead to major adverse outcomes.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Genetics & Heredity

Single-cell genomics meets human genetics

Anna S. E. Cuomo, Aparna Nathan, Soumya Raychaudhuri, Daniel G. MacArthur, Joseph E. Powell

Summary: In this Review, the authors discuss the field of single-cell genetics, which combines single-cell genomics with human genetics. They highlight the importance of single-cell expression quantitative trait loci studies in linking genetic variation to cellular processes in human biology and disease. The authors also mention the potential implications of this field for disease diagnosis, risk prediction, and therapeutic development, and emphasize the need for advances in data generation and analysis methods to fully utilize single-cell genomic data.

NATURE REVIEWS GENETICS (2023)

Article Rheumatology

Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application

Andrei Barbulescu, Arvid Sjolander, Benedicte Delcoigne, Johan Askling, Thomas Frisell

Summary: This study compared the incidence of serious infections between different oral glucocorticoid dose patterns in patients with rheumatoid arthritis. The results showed that higher doses and recent exposure to glucocorticoids are associated with an increased risk of serious infections. This study provides an explanation for the conflicting results in observational studies.

RHEUMATOLOGY (2023)

Letter Pediatrics

Incidence of Idiopathic Intracranial Hypertension in Individuals With Gonadotropin-Releasing Hormone Analogue Treatment for Gender Dysphoria in Sweden

Georgios Karamanis, Thomas Frisell, Mats Holmberg, Maria Halldin, Sara Sylven, Alkistis Skalkidou, Fotios C. Papadopoulos

Summary: This study investigates the occurrence of idiopathic intracranial hypertension (IHH) in individuals in Sweden who are undergoing gonadotropin-releasing hormone analogue (GnRHa) treatment for gender dysphoria.

JAMA PEDIATRICS (2023)

Article Biochemistry & Molecular Biology

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes

Alexandre Xavier, Vicki E. Maltby, Ewoud Ewing, Maria Pia Campagna, Sean M. Burnard, Jesper N. Tegner, Mark Slee, Helmut Butzkueven, Ingrid Kockum, Lara Kular, Vilija G. Jokubaitis, Trevor Kilpatrick, Lars Alfredsson, Maja Jagodic, Anne-Louise Ponsonby, Bruce V. Taylor, Rodney J. Scott, Rodney A. Lea, Jeannette Lechner-Scott

Summary: This study reveals that DNA methylation differences in multiple sclerosis (MS) occur independently of known genetic risk loci. It shows that these differences more effectively differentiate the disease compared to known genetic risk loci. The study also indicates that the methylation differences in MS predominantly occur in B cells and monocytes, involving cell-specific biological pathways.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Immunology

Prevention vs treatment of rheumatoid arthritis

Lars Klareskog, Lars Alfredsson

Summary: In the case of rheumatoid arthritis, the focus has mostly been on treating the established disease rather than preventing it. This review argues that prevention should become a major part of research and clinical practice, and describes the basis for broad public health-based prevention as well as a precision prevention strategy for individuals at high risk. The potential effectiveness of precision prevention will depend on the development of specific and long-lasting tolerance therapy.

IMMUNOTHERAPY ADVANCES (2023)

No Data Available